Interferon beta (IFNβ) is used in the treatment of multiple sclerosis (MS) because it can reduce relapse rate and lesion formation on MRI and can slow progression of the disease [1] [2] [3] . As has been observed with other protein-based drugs, some patients develop neutralizing antibodies (NAbs) during chronic administration of IFNβ. The proportion of patients developing NAbs ranges from 25% for the 3-times-weekly subcutaneous IFNβ-1a regimen to 2% for the once-weekly intramuscular IFNβ-1a regimen 4 . Published data from large, randomized clinical trials demonstrate that efficacy is reduced in patients who are NAbpositive (NAb+) compared with those who are NAb-negative (NAb-) 3, 5 . Neutralizing antibodies can potentially cross the blood-brain barrier (BBB) in IFNβ-treated patients with relapsing-remitting multiple sclerosis (RRMS) and impair endogenous IFNβ function within the central nervous system (CNS). This theory is supported by the results of a study by Shapiro et al. 6 , which demonstrated that in human astrocytes in culture, high serum titers of NAbs (1865-19,320 tenfold reduction units [TRU]) inhibit toll-like receptor-3 ligand and endogenous IFNβ-mediated production of CXCL10 and IL-6. Three patients with moderately high serum NAb and BAb titers were selected for further screening for BAbs and NAbs in the CSF: 2 patients treated with IFNβ-1b (titers of 570 TRU and >500 BTU, and 26 TRU and 35 BTU, respectively) and 1 patient treated with subcutaneous IFNβ-1a (titer of 489 TRU and >500 BTU). None of these patients were positive for BAbs in the CSF (Table) . dIscussIon This case study shows that patients with positive titers of NAbs and BAbs in serum did not have detectable NAbs and BAbs in the CSF. However, the absence of these antibodies in the CSF does not eliminate the possibility that antibodies can cross the BBB locally in the area of inflammation yet not reach detectable levels in the CSF.
